Related Experiment Video
Updated: Jun 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber
T Nishimoto1, K Yoshida, Y Miura
1Section for Studies on Host-Immune Response, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Abstract:
A conditionally replicative adenovirus is a novel anticancer agent designed to replicate selectively in tumor cells. However, a leak of the virus into systemic circulation from the tumors often causes ectopic infection of various organs. Therefore, suppression of naive viral tropism and addition of tumor-targeting potential are necessary to secure patient safety and increase the therapeutic effect of an oncolytic adenovirus in the clinical setting. We have recently developed a direct selection method of targeted vector from a random peptide library displayed on an adenoviral fiber knob to overcome the limitation that many cell type-specific ligands for targeted adenovirus vectors are not known. Here we examined whether the addition of a tumor-targeting ligand to a replication-competent adenovirus ablated for naive tropism enhances its therapeutic index. First, a peptide-display adenovirus library was screened on a pancreatic cancer cell line (AsPC-1), and particular peptide sequences were selected. The replication-competent adenovirus displaying the selected ligand (AdDeltaCAR-SYE) showed higher oncolytic potency in several other pancreatic cancer cell lines as well as AsPC-1 compared with the untargeted adenovirus (AdDeltaCAR). An intratumoral injection of AdDeltaCAR-SYE significantly suppressed the growth of AsPC-1 subcutaneous tumors, and an analysis of adenovirus titer in the tumors revealed an effective replication of the virus in the tumors. Ectopic liver gene transduction following the intratumoral injection of AdDeltaCAR-SYE was not increased compared with the AdDeltaCAR. The results showed that a tumor-targeting strategy using an adenovirus library is promising for optimizing the safety and efficacy of oncolytic adenovirus therapy.
Insights
Targeted oncolytic adenovirus therapy shows promise for cancer treatment. Adding a tumor-targeting ligand to a replication-deficient adenovirus enhanced its efficacy and safety, reducing off-target infections.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Cancer research
Background:
- Conditionally replicative adenoviruses are novel anticancer agents.
- Tumor-specific replication is essential for safety and efficacy.
- Off-target infections from systemic viral spread are a major concern.
Purpose of the Study:
- To investigate if adding a tumor-targeting ligand enhances the therapeutic index of replication-competent adenoviruses.
- To overcome limitations in identifying specific ligands for targeted adenovirus vectors.
Main Methods:
- Developed a direct selection method using a peptide library displayed on an adenoviral fiber knob.
- Screened a peptide-display adenovirus library on pancreatic cancer cells (AsPC-1).
- Evaluated the oncolytic potency and tumor suppression of the targeted adenovirus (AdDeltaCAR-SYE) in preclinical models.
Main Results:
- The targeted AdDeltaCAR-SYE demonstrated higher oncolytic potency against pancreatic cancer cell lines compared to the untargeted AdDeltaCAR.
- Intratumoral injection of AdDeltaCAR-SYE significantly suppressed tumor growth.
- Ectopic liver gene transduction was not increased, indicating improved safety.
Conclusions:
- A tumor-targeting strategy using an adenovirus library can optimize oncolytic adenovirus therapy.
- This approach enhances both safety and efficacy for cancer treatment.
- Targeted adenoviral vectors represent a promising strategy for improving cancer therapy.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

